Wellington Shields Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Wellington Shields Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.06M	Buy	31,985 +29,185	+1,042%	+$3.95M	0.64%	34
2026 Q1	$358K	Sell	2,800 -250	-8%	-$31.2K	0.05%	187
2025 Q4	$372K	Buy	+3,050	New	+$350K	0.05%	180
2024 Q3	–	Sell	-200	Closed	-$18.5K	–	327
2024 Q2	$18.5K	Hold	200	–	–	﹤0.01%	299
2024 Q1	$19K	Buy	+200	New	+$18.6K	﹤0.01%	294
2023 Q1	–	Sell	-350	Closed	-$29.1K	–	334
2022 Q4	$29.1K	Sell	350 -7,950	-96%	-$644K	﹤0.01%	287
2022 Q3	$658K	Buy	+8,300	New	+$700K	0.16%	118

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Wellington Shields Capital Management's XBI Position: Q2 2026 in Review

Wellington Shields Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1,042% in Q2 2026, buying an estimated $3.95M and bringing the position to 31,985 shares worth $5.06M. The position accounts for 0.64% of the portfolio, ranked #34.

Wellington Shields Capital Management first reported a position in XBI in Q3 2022 and has held it in 7 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Wellington Shields Capital Management held 31,985 shares of State Street SPDR S&P Biotech ETF worth $5.06M as of Q2 2026.
Wellington Shields Capital Management bought 29,185 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $3.95M.
State Street SPDR S&P Biotech ETF made up 0.64% of Wellington Shields Capital Management's portfolio in Q2 2026, its #34 holding.
Wellington Shields Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and has held it in 7 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Wellington Shields Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.